Metabolic therapy of heart failure

Gabriele Fragasso, Anna Salerno, Roberto Spoladore, Giorgio Bassanelli, Francesco Arioli, Alberto Margonato

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Alterations of cardiac metabolism can be present in several cardiac syndromes. Heart failure may itself promote metabolic changes such as insulin resistance, in part through neurohumoral activation, and determining an increased utilization of non-carbohydrate substrates for energy production. In fact, fasting blood ketone bodies as well as fat oxidation have been shown to be increased in patients with heart failure. The result is depletion of myocardial ATP, phosphocreatine and creatine kinase with decreased efficiency of mechanical work. A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the failing heart. To date, the most effective metabolic treatments include several pharmacological agents, such as trimetazidine and perhexiline, that directly inhibit fatty acid oxidation. These agents have been originally adopted to increase the ischemic threshold in patients with effort angina. However, the results of current research is supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism could be an effective adjunctive treatment in patients with heart failure, in terms of left ventricular function and glucose metabolism improvement. In fact, these agents have also been shown to improve overall glucose metabolism in diabetic patients with left ventricular dysfunction. In this paper, the recent literature on the beneficial therapeutic effects of modulation of cardiac metabolic substrates utilization in patients with heart failure is reviewed and discussed.

Original languageEnglish
Pages (from-to)2582-2591
Number of pages10
JournalCurrent Pharmaceutical Design
Volume14
Issue number25
DOIs
Publication statusPublished - 2008

Fingerprint

Heart Failure
Glucose
Fatty Acids
Perhexiline
Trimetazidine
Therapeutics
Ketone Bodies
Phosphocreatine
Left Ventricular Dysfunction
Therapeutic Uses
Creatine Kinase
Left Ventricular Function
Energy Metabolism
Insulin Resistance
Fasting
Adenosine Triphosphate
Fats
Pharmacology
Research

Keywords

  • Carnitine palmitoyl transferase I (CPT-I)
  • Free fatty acids inhibitors
  • Heart failure
  • Left ventricular function
  • Metabolic therapy
  • Myocardial metabolism
  • Trimetazidine

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Metabolic therapy of heart failure. / Fragasso, Gabriele; Salerno, Anna; Spoladore, Roberto; Bassanelli, Giorgio; Arioli, Francesco; Margonato, Alberto.

In: Current Pharmaceutical Design, Vol. 14, No. 25, 2008, p. 2582-2591.

Research output: Contribution to journalArticle

Fragasso, G, Salerno, A, Spoladore, R, Bassanelli, G, Arioli, F & Margonato, A 2008, 'Metabolic therapy of heart failure', Current Pharmaceutical Design, vol. 14, no. 25, pp. 2582-2591. https://doi.org/10.2174/138161208786071245
Fragasso, Gabriele ; Salerno, Anna ; Spoladore, Roberto ; Bassanelli, Giorgio ; Arioli, Francesco ; Margonato, Alberto. / Metabolic therapy of heart failure. In: Current Pharmaceutical Design. 2008 ; Vol. 14, No. 25. pp. 2582-2591.
@article{76352d786b4f456ab941270e7586da04,
title = "Metabolic therapy of heart failure",
abstract = "Alterations of cardiac metabolism can be present in several cardiac syndromes. Heart failure may itself promote metabolic changes such as insulin resistance, in part through neurohumoral activation, and determining an increased utilization of non-carbohydrate substrates for energy production. In fact, fasting blood ketone bodies as well as fat oxidation have been shown to be increased in patients with heart failure. The result is depletion of myocardial ATP, phosphocreatine and creatine kinase with decreased efficiency of mechanical work. A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the failing heart. To date, the most effective metabolic treatments include several pharmacological agents, such as trimetazidine and perhexiline, that directly inhibit fatty acid oxidation. These agents have been originally adopted to increase the ischemic threshold in patients with effort angina. However, the results of current research is supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism could be an effective adjunctive treatment in patients with heart failure, in terms of left ventricular function and glucose metabolism improvement. In fact, these agents have also been shown to improve overall glucose metabolism in diabetic patients with left ventricular dysfunction. In this paper, the recent literature on the beneficial therapeutic effects of modulation of cardiac metabolic substrates utilization in patients with heart failure is reviewed and discussed.",
keywords = "Carnitine palmitoyl transferase I (CPT-I), Free fatty acids inhibitors, Heart failure, Left ventricular function, Metabolic therapy, Myocardial metabolism, Trimetazidine",
author = "Gabriele Fragasso and Anna Salerno and Roberto Spoladore and Giorgio Bassanelli and Francesco Arioli and Alberto Margonato",
year = "2008",
doi = "10.2174/138161208786071245",
language = "English",
volume = "14",
pages = "2582--2591",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "25",

}

TY - JOUR

T1 - Metabolic therapy of heart failure

AU - Fragasso, Gabriele

AU - Salerno, Anna

AU - Spoladore, Roberto

AU - Bassanelli, Giorgio

AU - Arioli, Francesco

AU - Margonato, Alberto

PY - 2008

Y1 - 2008

N2 - Alterations of cardiac metabolism can be present in several cardiac syndromes. Heart failure may itself promote metabolic changes such as insulin resistance, in part through neurohumoral activation, and determining an increased utilization of non-carbohydrate substrates for energy production. In fact, fasting blood ketone bodies as well as fat oxidation have been shown to be increased in patients with heart failure. The result is depletion of myocardial ATP, phosphocreatine and creatine kinase with decreased efficiency of mechanical work. A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the failing heart. To date, the most effective metabolic treatments include several pharmacological agents, such as trimetazidine and perhexiline, that directly inhibit fatty acid oxidation. These agents have been originally adopted to increase the ischemic threshold in patients with effort angina. However, the results of current research is supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism could be an effective adjunctive treatment in patients with heart failure, in terms of left ventricular function and glucose metabolism improvement. In fact, these agents have also been shown to improve overall glucose metabolism in diabetic patients with left ventricular dysfunction. In this paper, the recent literature on the beneficial therapeutic effects of modulation of cardiac metabolic substrates utilization in patients with heart failure is reviewed and discussed.

AB - Alterations of cardiac metabolism can be present in several cardiac syndromes. Heart failure may itself promote metabolic changes such as insulin resistance, in part through neurohumoral activation, and determining an increased utilization of non-carbohydrate substrates for energy production. In fact, fasting blood ketone bodies as well as fat oxidation have been shown to be increased in patients with heart failure. The result is depletion of myocardial ATP, phosphocreatine and creatine kinase with decreased efficiency of mechanical work. A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the failing heart. To date, the most effective metabolic treatments include several pharmacological agents, such as trimetazidine and perhexiline, that directly inhibit fatty acid oxidation. These agents have been originally adopted to increase the ischemic threshold in patients with effort angina. However, the results of current research is supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism could be an effective adjunctive treatment in patients with heart failure, in terms of left ventricular function and glucose metabolism improvement. In fact, these agents have also been shown to improve overall glucose metabolism in diabetic patients with left ventricular dysfunction. In this paper, the recent literature on the beneficial therapeutic effects of modulation of cardiac metabolic substrates utilization in patients with heart failure is reviewed and discussed.

KW - Carnitine palmitoyl transferase I (CPT-I)

KW - Free fatty acids inhibitors

KW - Heart failure

KW - Left ventricular function

KW - Metabolic therapy

KW - Myocardial metabolism

KW - Trimetazidine

UR - http://www.scopus.com/inward/record.url?scp=57349127248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349127248&partnerID=8YFLogxK

U2 - 10.2174/138161208786071245

DO - 10.2174/138161208786071245

M3 - Article

C2 - 18991675

AN - SCOPUS:57349127248

VL - 14

SP - 2582

EP - 2591

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 25

ER -